GlaxoSmithKline says Avandia reduces risk of type 2 diabetes

By Lisa Kerner

Charlotte, N.C., Sept. 15 - GlaxoSmithKline said Avandia (rosiglitazone maleate) reduced the risk of developing type 2 diabetes by 62% compared to a placebo in patients at high risk of developing the disease, according to the results of the study known as Dream.

The Dream (diabetes reduction assessment with ramipril and rosiglitazone medication) trial evaluated 5,269 participants with a condition known as pre-diabetes, where blood sugar levels are higher than normal but not high enough for a diabetes diagnosis.

The London pharmaceutical company said patients were randomized to receive rosiglitazone (8 mg daily) or a placebo and to ramipril (15 mg daily) or a placebo for three to five years.

In the rosiglitazone arm, 10.6% of participants progressed to type 2 diabetes compared to 25% of those treated with a placebo.

Over the three-year median follow-up period, 51% of subjects receiving rosiglitazone returned to normal blood sugar levels compared to 30% of those in the placebo arm.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.